Research Reports

AMSS surged +116% after Good Twin Wine was announced as the #1 organic non-alcoholic wine brand in the U.S. — a category so niche it's essentially meaningless. The stock direct listed at $17 on May 20, crashed to $3.50 in a week, and is now bouncing on a press release. Revenue has collapsed 47% from $33.5M to $17.8M over two years. Gross margins fell from 32% to 21%. The company loses $14.6M annually and just filed an 8-K for a $6.99M Series C convertible preferred raise — dilutive. The non-alc beverage trend is real, but AMASS is a value-destroying brand aggregator with deteriorating fundamentals. Avoid.

CODX surged +30% on the CoMira Saudi JV moving to execution phase and an ESCMID presentation. But Q1 2026 revenue was $146,000. That's not a typo. The company lost $9.1M in the quarter on $146K in revenue — a 62,000% loss-to-revenue ratio. Revenue has collapsed 99.8% from its $298M FY2021 COVID peak. The Saudi manufacturing JV is real but years from generating meaningful revenue. Co-Dx PCR platform needs FDA submission, clinical validation, and commercial scaling — all uncertain. At ~$52M market cap for a company with $720K TTM revenue, CODX is massively overvalued. Avoid.

MetaVia surged +42% after presenting DA-1726 (a GLP-1/glucagon dual agonist for obesity) and vanoglipel (GPR119 agonist for diabetes) data at ADA 2026. Fein reiterated Buy with a $20 PT. The GLP-1 market is a $100B+ opportunity and DA-1726's once-weekly oxyntomodulin analog is differentiated from Wegovy/Zepbound. But: zero revenue, $13.7M annual loss, 139% share dilution, Phase 1 only, and a stock that traded at $1.4M/share pre-split. The $20 PT requires DA-1726 to succeed in Phase 2/3 and compete against Eli Lilly and Novo Nordisk. At $8M market cap, the option value is cheap but the binary risk is extreme. Speculative Buy for risk capital only.

Entravision surged +74% after Q1 2026 earnings showed revenue +114% to $197M and a swing to profitability ($12.4M net income). The story isn't Spanish-language TV and radio anymore — it's ATS (AdTech Services), which grew revenue +204% to $154.6M and now represents 79% of total revenue. Programmatic advertising to mobile app developers is scaling explosively. Operating income of $20.7M is a 427% improvement. The company still pays a $0.05 dividend. At 0.76x TTM revenue with accelerating growth, EVC is one of the cheapest high-growth adtech stories in the market. Bullish.

Cue Biopharma surged +93% after announcing a $30M private placement and receiving a $7.5M milestone payment for CUE-401/CUE-501 preclinical programs. The company is a clinical-stage biotech developing T-cell engagers for cancer and autoimmune disease, partnered with Bristol Myers Squibb on CUE-102. Revenue of $27.5M in FY2025 is entirely milestone/collaboration income — zero product sales. The company burns $37.7M annually on R&D alone. The $30M financing extends runway but the 3.22M share count has grown 68% YoY through dilution. At $92M market cap, CUE is pricing in clinical success that hasn't happened yet. Neutral.

SNBR surged +27% ahead of Q1 earnings (April 29) as the market prices in a potential floor. Revenue declined 16% to $1.41B in FY2025 with a $132M net loss. The smart bed category pioneer is losing market share to cheaper foam mattresses and DTC brands. Analyst consensus is Hold with a $4.50 price target. CEO has guided for Q2 stabilization. At $64M market cap and $22.9M shares, the stock is a binary pre-earnings bet. Neutral — the fundamentals are deteriorating but the downside at $2.80 may be limited if Q1 shows stabilization.

SEGG surged +27% on the launch of Sports.com Predict, a sports predictions platform targeting the 2026 FIFA World Cup. The company owns Sports.com, Concerts.com, TicketStub.com, and Lottery.com — valuable domain names attached to a business with $0.9M TTM revenue, ($20.8M) net loss, 12 employees, and 284% share dilution YoY. Revenue has collapsed 84% in the last year. The NASDAQ has issued a delisting notice for late 10-K filing. This is a domain-name hype stock with no revenue model that works. Avoid.

BBBY surged +30% after Q1 2026 earnings showed the first revenue growth in 19 quarters (+6.9% to $247.8M) with net loss narrowing to $16.4M and $163M cash. This is Beyond Inc. (formerly Overstock) that acquired the Bed Bath & Beyond IP out of bankruptcy and is rebuilding the brand online + physical stores. CEO Marcus Lemonis targets 6-7% EBITDA margins. Revenue is still 62% below pre-bankruptcy levels, the company burns $61M/year, and gross margins are a thin 23.9%. But the turnaround thesis is showing early signs of life. Speculative Buy for risk capital.

Aterian announced a definitive agreement to sell its Marquee Brand Portfolio for $18M — 2.5x the company's $7M market cap. Combined with $7.6M in existing cash, total distributable assets could reach $25M+ against a $7M valuation. Revenue has collapsed 72% from peak ($248M → $69M), but the brand sale marks the start of a structured wind-down. The strategic alternatives review is delivering concrete results. Key risks: remaining debt, wind-down costs, and whether the $18M is subject to adjustments that reduce proceeds. Speculative but the math is compelling.

FreeCast surged +40% on a national distribution agreement with DIRECTV Multifamily. The deal is real — but the company has $628K in annual revenue, $433K in cash, and burns $14M/year. Being an 'authorized distributor' of DIRECTV streaming doesn't change the math: FreeCast is a commission-taking middleman with no pricing power, no scale, and no path to profitability. The 60% insider ownership means retail is trapped. At 162x revenue, this is one of the most overvalued stocks we've covered. Avoid.

Allbirds agreed to sell all assets to American Exchange Group (AXNY) for $39M and dissolve the company. Distributions expected Q3 2026. At the current ~$2.51 price, the implied value per share depends entirely on residual cash, tax assets (NOLs), and wind-down costs. William Blair estimates ~$5.70/share fair value including NOLs. But the $39M sale is only ~$0.44/share before expenses. This is a liquidation arb — not an operating investment. Neutral.

RCT is up +122.81% pre-market after signing a $30M, 5-year Saudi Arabia licensing deal to deploy its RAID AI engine across a $68B FMCG market. This is RedCloud's second major JV in four months, bringing combined contracted JV infrastructure revenue to $80M — not bad for a stock that was trading at $0.68 yesterday.

OMEX surged +144% on a $1B merger with AOMC to create American Ocean Minerals Corporation — a deep-sea critical minerals platform targeting polymetallic nodules for battery metals and phosphate for fertilizer. 30+ years of offshore operating experience. Cook Islands nodule JV with a $4.7B JORC resource estimate. Trump pro-mining executive order tailwind. Binary bet on seafloor mining. Speculative only.

ADVB surged +63% on April 7, 2026 with no identifiable company-specific news, press release, or filing. This is a pre-revenue Taiwan-based microfluidic biochip company with 1.36M shares, 31 employees, zero revenue, and TTM 'net income' of $4.39M that is entirely driven by a one-time $7.41M non-operating income item. Operating losses are ($2.9M). FCF is ($6.11M). The stock crashed from a 52-week high of $75.40 to $3.61 before today's pop. Avoid.

TMD Energy surged +57% on pure macro oil momentum. The valuation anomaly is real: $607M TTM revenue at a $25M market cap (0.04x P/S). But it's a marine fuel bunkering company with 2.4% gross margins, net losses, negative FCF, and no pricing power. Revenue is throughput, not value creation.

Sky Quarry surged +104% on a PR touting its Nevada refinery's 'strategic value' as Brent tops $110. The reality: 5,000 bpd permitted capacity in a 300,000+ bpd state, revenue declining 47% YoY, negative gross margins, -$12.2M net loss, and digital tokenization side projects. This is a promotion, not an investment.

CYCN surged +185% on an all-stock merger with Korsana Biosciences, a private neurodegenerative disease company targeting amyloid beta for Alzheimer's. $380M concurrent private financing funds operations through 2029 with clinical data readouts in 2027. Binary bet on neurodegeneration — well-funded but pre-clinical.

nCino crushed Q4 FY2026 earnings — EPS $0.37 vs $0.21 expected, ACV +17% YoY, $100M buyback launched. FY2027 guidance: $639-643M revenue, $132-137M FCF. Cloud banking SaaS at profitability inflection with 112% net retention. Underfollowed fintech at 12.8x forward FCF.

Target Hospitality surged +35% after landing a $550M+ multi-year contract with a top-5 hyperscaler to build a 4,000-person modular accommodations campus for North Texas data center workers. Second hyperscaler deal in 8 months. Zero net debt, $183M liquidity. The pivot from oilfield housing to AI infrastructure enabler is signed paper now — not just narrative.

BFRG surged 126%+ on a 'top-5 pharma deal' for MDD target identification. The 8-K reveals it's actually a Feasibility Agreement — a paid pilot, not a commercial contract. $120K annual revenue, $6.6M burn, ~3.5 months runway, dual Nasdaq delisting risks, 9 employees. Avoid.

Sound Group surged +32% on 53% revenue growth and a return to profitability. But the Big Four auditor quit over cash disputes, RMB 90.7M vanished, and US investors own a Cayman shell. The numbers look great on paper — you just can't trust them.

Hong Kong digital marketing firm with 7 employees, revenue cut in half, and mounting losses. Recent 1-for-16 reverse split signals desperation to maintain Nasdaq listing. Fundamental deterioration and micro-cap risks make this uninvestable.

Community oncology leader hit first profitable quarter (Adj. EBITDA) in Q4 2025. Revenue +28% to $503M with expanding capitated contracts. 2026 guidance targets $630-650M revenue and positive Adj. EBITDA.

Clinical-stage biotech with Phase 3 itolizumab data and potential BLA submission in H1 2026. $50M raise extends runway to 2027, but no approved products and continued cash burn make this a binary outcome play.

Polar Power is up 12.9% on 20M+ shares in pre-market trading, but there's no specific catalyst. The company manufactures DC power systems for telecom, military, and renewable applications, but has no earnings news and faces Nasdaq delisting risk. This is speculation, not investment.

Codexis just delivered a Q4 beat with 81% revenue growth, guided $72-76M for 2026, and has $78M cash through 2027. The ECO Synthesis platform is scaling from 100-gram to half-kilogram production, and a Merck deal added $38M in non-dilutive capital. This is an RNA manufacturing thesis.

Tilly's just shocked the market with a Q4 beat that sent shares up 81% overnight. Same-store sales jumped 10%, gross margins are expanding, and management sees a clear path to annual profitability. This isn't your typical mall retailer story.

Clinical-stage biotech trading at 1x cash with three differentiated platforms — Kv7 epilepsy, extracellular protein degraders, and ADCs — all hitting pivotal data in H2 2026. Opakalim's 40x therapeutic index edge in epilepsy could be worth $2-3B alone.

EON Resources operates 1,000+ bbl/day from 20,000 Permian Basin acres with a $300M Virtus farmout underway, $37M in debt retired, and 60% of 2026 production hedged at $60+. The market is pricing this at $18M. The NPV-10 alone is >$95M.

TPET spiked 318% in a week on Alberta well news. The problem: those wells produce 30-40 barrels per day, and the company lost $2.71M on $398K in quarterly revenue. The math says fade this move.

Spanish AI-solar storage company with a $53M signed industrial backlog trading at an $18.5M market cap. Revenue growing, losses narrowing 51% — but Nasdaq compliance risk is real and must be watched.

Can-Fite surged +142% pre-market after Phase IIa namodenoson in advanced pancreatic cancer met safety endpoint. The real catalyst: Phase III HCC interim expected Q4 2026. A3AR agonist platform with clean safety across 1,600+ patients. Speculative Buy for risk capital only.

Moolec surged 90% on validated 45% GLA concentration from engineered safflower at commercial scale. The science is real — 1,100 acres, standard crushing infrastructure, genuinely differentiated molecular farming. But a $7M market cap, going concern language, and a June 2026 Nasdaq deadline make this a watch-and-wait.

CDIO is up +25% pre-market on heavy volume as momentum continues from the company's Feb 19 investor call showcasing AI-driven coronary heart disease tests with preliminary CMS reimbursement approval in hand. At a $9.5M market cap, the risk/reward is asymmetric — if Medicare reimbursement finalizes, this company is worth multiples of today's price.

Searchlight Capital and Abry Partners are acquiring KORE at $9.25/share — a 691% premium to the December 2024 unaffected price — validating that this pure-play IoT hyperscaler was trading at a fraction of its strategic value.

TheRealReal crushed Q4 2025 estimates — $194M revenue (+18% YoY), non-GAAP EPS of $0.06 vs. $0.04 consensus — delivering the first full year of positive adjusted EBITDA in company history. The market is waking up to the fact that luxury resale has a dominant, defensible platform, and REAL just proved it can make money.

RBNE is up +6.5% pre-market as momentum builds ahead of Q4 earnings — the first quarter to fully reflect its three-vessel LPG and tanker fleet. The real story: a debt-free operator with $5.5M in locked 2026 charters trading at 22 cents on the dollar of net asset value.

LASE is up +6.8% in pre-market after landing a repeat CMS Laser marking order from a fiber optic manufacturer with 20+ installed systems — validating enterprise traction despite a turbulent year that included a financial restatement, securities investigations, and a dilutive $5M equity raise.

GCT surged +32.4% on record Q4 earnings — EPS of $1.04 crushed estimates by 40.5%. At 13x trailing earnings with zero debt and $417M cash, this B2B large-parcel marketplace is the most undervalued profitable small-cap we've covered.

DNUT surged +28.6% on 19.1M shares — 7-9x average volume — after Q4 2025 adjusted EPS of $0.09 demolished the $0.03 consensus by 200%. Adjusted EBITDA margin expanded 280 basis points to 14.2% and free cash flow turned positive at $27.9 million. After a brutal year dominated by the McDonald's partnership collapse, Krispy Kreme's Q4 is the first hard evidence the turnaround is real.

Acadia Healthcare trades at a steep discount to intrinsic value as DOJ/SEC investigations weigh on sentiment, but record $3.2B revenue and growing behavioral health demand create an asymmetric risk/reward setup.

Clinical-stage biopharma focused on inflammatory diseases surged 20.5% in pre-market on momentum from recent positive mechanism-of-action data for lead drug rademikibart. Phase 1b IV data expected Q1 2026, Phase 2 Seabreeze STAT readouts mid-2026. Cash runway into 2027 provides cushion through catalysts.

ANPA provides financial printing and corporate services in Hong Kong with nascent Web3 ambitions. Despite recent volatility-driven gains, the company's extreme P/E ratio of ≈5,842, declining earnings, and small scale warrant caution.

Autonomous sidewalk delivery robot maker surged 67.5% in pre-market after announcing Q4 earnings scheduled for March 11. With 2,000 robots deployed via Uber Eats and DoorDash partnerships, 10x revenue growth expected in 2026. The Physical AI thesis is driving momentum.

Nano-cap security robotics company surged 20.2% in pre-market, building on 43% gains from last week's $5M share buyback announcement. Trading below $1 with Nasdaq compliance deadline June 2026, the company is expanding AI/robotics into Hong Kong, Singapore, and Taiwan while pursuing acquisitions.

Palvella's QTORIN rapamycin platform shows compelling Phase 2 data in rare skin diseases with zero FDA-approved treatments, positioning the company for potential accelerated approval pathways.

BNAI surged over 80% after terminating a $50M equity purchase agreement, signaling management's confidence and removing dilution overhang. The conversational AI company serves automotive, healthcare, and financial services verticals.

Global turbocharging leader surged 12.0% in pre-market after Q4 2025 earnings beat estimates ($0.42 vs $0.37 expected). Despite a -7.3% post-earnings sell-off last week, fundamentals remain strong: $3.58B revenue, $510M adjusted EBIT, $403M free cash flow, and 8% share reduction in 2025. New $250M buyback authorized for 2026. The dip offers an attractive entry point for a quality industrial with electrification upside.

Once-promising drive-thru voice AI company is essentially defunct, trading at $0.0001 per share with a ≈$200 market cap. Delisted from Nasdaq and now on OTC Pink Sheets, the company faces severe liquidity crisis and potential bankruptcy. The 16.5% pre-market move has no fundamental meaning—this is a zombie stock.

Unisys beat profitability guidance, slashed its pension deficit by $300M, and holds $414M in cash — yet trades at just 0.09x revenue. A turnaround story with real catalysts.

Rigetti's modular chiplet architecture and international expansion position it as a key quantum infrastructure player, with a $5.48B valuation reflecting both promise and volatility.

Sigma Lithium operates one of the largest hard-rock lithium projects in the Americas but faces severe margin compression. A speculative bet on lithium price recovery with meaningful operational leverage.

Singapore-based health tech company surged 12.9% in pre-market following expansion into stem cell therapy and regenerative medicine. The company recently opened a clinic in Shenzhen and secured a Malaysia direct selling license for its longevity products. While the longevity market is growing, EUDA's business model combines direct selling, clinic operations, and digital health—a complex structure that has yet to demonstrate profitability.

Nano-cap furniture company surged 13.0% in pre-market after announcing a $5.66M investment in a fund holding SpaceX shares. The company recently raised $9M through a public offering, with most proceeds going toward this speculative SpaceX exposure. While the SpaceX brand attracts attention, this represents a radical strategic pivot from a furniture business with minimal revenue and questionable fundamentals.

Vir's infectious disease pipeline trades at a fraction of analyst price targets, with $68.5M in 2025 revenue and programs targeting hepatitis delta, influenza, and novel antibody approaches.

D-Wave has achieved what competitors haven't: real commercial revenue from production quantum workloads, with 100+ organizations actively using its systems and 100% YoY revenue growth.

GBIO announced a 90% workforce reduction and strategic review as it struggles to extend its cash runway, raising significant concerns about the company's ability to continue as a going concern.

GANX reported positive Phase 1b results for GT-02287 in Parkinson's disease, showing first-ever reduction in GCase substrate in CSF, validating the drug's mechanism of action.

Trading at $1.95 with a $10.6M market cap and analyst targets of $13, Edesa offers 760% potential upside if Phase 3 programs in ARDS and dermatitis succeed.

Claritev (formerly MultiPlan) delivered turnaround 2025 results with narrowing losses and $25B in identified medical cost savings, but significant debt and competitive pressures warrant a cautious stance.

Clarivate reported Q4 2025 earnings beating expectations while exploring a potential sale of its Life Sciences segment, but the stock remains pressured by debt concerns and strategic uncertainty.

A $7-10M market cap bitcoin miner doing $7.4M in LTM revenue with sub-$0.04/kWh power costs, two Tennessee facilities, and operating profit up 207% YoY. Trades below book value. The catch: $94K cash and a $3M loan at 12%.

KNRX surged 245% on an 'agentic AI' API launch, but underneath the buzzword sits $0.2M cash, $8.2M debt, shrinking revenue, and 2-3 weeks of runway. We break down why the narrative doesn't match the balance sheet.

Rackspace surged 229% after announcing a Palantir partnership to deploy managed AI for regulated enterprises. At 0.12x trailing P/S with $2.5B in debt, this is either the most credible turnaround catalyst since the re-IPO or a dead cat bounce on a hail mary press release.

A $127M micro-cap with $65K in annual revenue just spiked 41% because its quantum-engineered silicon film may solve the biggest manufacturing challenge in 2nm Gate-All-Around chips. The science is real. The financials are terrifying. Here's why that might not matter.

A $168M market cap company holding 1,000 BTC (≈$89M) and building the first retail tokenized deposit platform with Uphold and Vast Bank. CEO Greg Kidd was first money into Twitter, Square, Coinbase, Ripple, and Solana. At $0.42, you're getting the deposit business for free.

$14.9B in revenue last year — tripled YoY — yet the stock trades at 8x earnings because of an auditor change and a DOJ inquiry. We dug into the filings to separate the governance noise from the business reality.

A $25M market cap company with a SaaS product growing 45% YoY at 72% gross margins — and zero analyst coverage. Their DataV IoT platform is quietly replacing legacy device management across industrial customers.

Uranium spot hit $90/lb and Ur-Energy produces at $28/lb. That's a 61% gross margin on a commodity with a structural supply deficit. Every $10/lb move in uranium adds $6M to their EBITDA — and most analysts expect $100+ by 2027.

For every barrel of Permian oil, 4-6 barrels of water come up — and disposing of it is legally required. Aris runs 1,500 miles of pipeline handling 1.2M barrels/day on 85% take-or-pay contracts. It's a regulated utility disguised as an oilfield services stock, trading at 8x EBITDA.

Down 85% from its 2021 peak, BioAtla trades at $35M enterprise value — less than zero after you back out cash. Two new clinical programs enter readouts in 2026. If either works, you're looking at a 3-5x. If not, you still have $2.20/share in cash.

Enterprise value: $7M. Target market: $5B+. Liminal's first-in-class OXER1 inhibitor for pulmonary fibrosis has orphan drug status and 2.7 years of cash runway — no dilution needed to reach Phase 2 data. The risk/reward math at this valuation is hard to ignore.